A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer.

BMC Genomics. 2013;14 Suppl 6:S5. doi: 10.1186/1471-2164-14-S6-S5. Epub 2013 Oct 25.

Barh D, Jain N, Tiwari S, Field JK, Padin-Iruegas E, Ruibal A, López R, Herranz M, Bhattacharya A, Juneja L, Viero C, Silva A, Miyoshi A, Kumar A, Blum K,Azevedo V, Ghosh P, Liloglou T.

Abstract

Lung cancer accounts for the highest number of cancer-related deaths worldwide. Early diagnosis significantly increases the disease-free survival rate and a large amount of effort has been expended in screening trials and

the development of early molecular diagnostics. However, a gold standard diagnostic strategy is not yet available. Here, based on miRNA expression profile in lung cancer and using a novel in silico reverse-transcriptomics

approach, followed by analysis of the interactome; we have identified potential transcription factor (TF) markers that would facilitate diagnosis of subtype specific lung cancer. A subset of seven TF markers has been used in

a microarray screen and was then validated by blood-based qPCR using stage-II and IV non-small cell lung carcinomas (NSCLC). Our results suggest that overexpression of HMGA1, E2F6, IRF1, and TFDP1 and downregulation

or no expression of SUV39H1, RBL1, and HNRPD in blood is suitable for diagnosis of lung adenocarcinoma and squamous cell carcinoma sub-types of NSCLC. Here, E2F6 was, for the first time, found to be upregulated in

NSCLC blood samples. The miRNA-TF-miRNA interaction based molecular mechanisms of these seven markers in NSCLC revealed that HMGA1 and TFDP1 play vital roles in lung cancer tumorigenesis. The strategy developed

in this work is applicable to any other cancer or disease and can assist in the identification of potential biomarkers.

PMID:24564251  [PubMed - indexed for MEDLINE]